Hydrocodone shows up on a drug test only if the panel is built to look for it. A classic opiate (OPI) immunoassay is calibrated to morphine, and hydrocodone does not reliably trigger it. That gap surprised so many employers and clinics that federal regulators rebuilt the standard opioid panel around it. Understanding which panel your program runs, and which cutoffs apply, is the difference between a screen that catches hydrocodone use and one that quietly lets it pass.
Why the classic OPI immunoassay misses hydrocodone
The traditional opiate screen used on most drug test panels is an immunoassay built around one target analyte group: codeine and morphine. The antibodies in that assay are selected for their affinity to morphine's molecular structure, and they cross-react well with codeine because codeine metabolizes partly into morphine. Hydrocodone, oxycodone, and other semi-synthetic opioids have a different ring structure, so they do not bind the same antibodies at a level that reliably triggers a positive result. A person taking a prescribed hydrocodone combination product can pass a standard OPI screen even though hydrocodone is present in their urine.
This limitation is documented directly in clinical toxicology literature. As one NIH reference on drug testing methodology explains, the opiate screen used in standard urine drug testing specifically detects morphine, and consequently does not reliably detect synthetic opioids such as fentanyl and methadone, or other structurally dissimilar opioids including buprenorphine, oxycodone, and hydrocodone, per the NCBI Bookshelf overview of drug testing methods. For any program that wants to catch hydrocodone specifically, the OPI panel alone is not the right tool.
The DOT expansion: hydrocodone, hydromorphone, oxycodone, and oxymorphone added to the panel
Regulators addressed this gap by adding four Schedule II semi-synthetic opioids as their own analyte groups. The Department of Health and Human Services first authorized federal executive branch agencies to test civilian employees for hydrocodone, hydromorphone, oxycodone, and oxymorphone, effective October 1, 2017, according to the SAMHSA frequently asked questions on federal workplace drug testing.
The Department of Transportation followed with its own rulemaking to harmonize 49 CFR Part 40 with the revised HHS guidelines. The final rule amended the DOT drug testing panel to add hydrocodone, hydromorphone, oxymorphone, and oxycodone, and it took effect January 1, 2018, per the Federal Register final rule on the DOT drug testing panel expansion. Every DOT-regulated safety-sensitive employee, including drivers, pilots, and mariners subject to 49 CFR Part 40, has been tested under this expanded panel since that date. The full regulatory text governing DOT collection and testing procedures is codified at 49 CFR Part 40 in the Electronic Code of Federal Regulations.
This change did not simply widen an existing category. It created two new analyte groups alongside the older codeine/morphine group, so a modern regulated panel screens opiates in three separate lanes rather than one.
How HYD and OXY panels are calibrated and cut off
Hydrocodone and hydromorphone share one immunoassay group because hydromorphone is hydrocodone's active metabolite, and the two compounds cross-react well with each other. Oxycodone and oxymorphone form a second, separate group for the same reason. The HHS Mandatory Guidelines set an initial screening cutoff of 300 ng/mL for the hydrocodone/hydromorphone group, with a confirmatory cutoff of 100 ng/mL for each analyte individually. The oxycodone/oxymorphone group carries a lower initial screening cutoff of 100 ng/mL, also confirmed at 100 ng/mL per analyte. These figures come directly from the cutoff table published in the Federal Register notice establishing the revised HHS Mandatory Guidelines cutoff concentrations. The older codeine/morphine group remains calibrated at a 2,000 ng/mL initial cutoff, confirmed at 2,000 ng/mL for each analyte, which is part of why it was never sensitive to the semi-synthetic opioids in the first place.
Panel comparison: OPI screen vs expanded opioid panel
| Panel component | Target analyte(s) | Initial screen cutoff | Detects hydrocodone? |
|---|---|---|---|
| Classic OPI (opiate) screen | Codeine, morphine | 2,000 ng/mL | Not reliably. Different molecular structure limits cross-reactivity. |
| HYD panel (hydrocodone/hydromorphone group) | Hydrocodone, hydromorphone | 300 ng/mL (100 ng/mL confirmatory per analyte) | Yes, this is the group built specifically to catch it. |
| OXY panel (oxycodone/oxymorphone group) | Oxycodone, oxymorphone | 100 ng/mL | No. Separate compound, separate group, does not cross-react with hydrocodone. |
| 6-AM (heroin marker) | 6-monoacetylmorphine | 10 ng/mL | No. Specific to heroin use, not hydrocodone. |
The practical takeaway for buyers is that "opiate panel" and "opioid panel" are not interchangeable terms. A program that wants hydrocodone coverage needs a cup or panel that explicitly lists HYD as a target analyte, not just OPI. The OXY group deserves its own attention too, since it is a separate compound with its own cutoff and its own detection profile, covered in more depth in this breakdown of how OXY panels compare to standard opiate screens. American Screening Corp's drug testing collection includes multi-panel cups with dedicated HYD and OXY lines so programs are not relying on an old-style OPI strip to catch a modern prescription opioid.
Metabolites: hydromorphone and norhydrocodone
Hydrocodone is metabolized in the liver through two main pathways. The CYP2D6 enzyme converts a portion of hydrocodone into hydromorphone, its active metabolite, and pain relief correlates more closely with hydromorphone plasma concentration than with the parent drug. A separate pathway, mediated by CYP3A4, converts hydrocodone into norhydrocodone, an inactive metabolite that does not contribute to analgesic effect. This dual metabolism is described in the NCBI Bookshelf clinical reference on hydrocodone pharmacology. Because hydromorphone appears in urine as a direct metabolite of hydrocodone, a positive hydromorphone result on its own does not distinguish hydrocodone use from separately prescribed hydromorphone. That distinction is one reason confirmatory testing and MRO interview both matter before any result is reported as verified positive.
Genetic variation in CYP2D6 activity means two people taking the same hydrocodone dose can produce noticeably different hydromorphone concentrations, which is part of why cutoff levels are set with a margin rather than at the lowest detectable trace. Elimination is fairly fast for immediate-release formulations given their short half-life, so urine detection for a single dose generally clears within the first few days after use, while regular or higher-dose use can extend that window somewhat, consistent with the pharmacokinetic profile in the same reference.
Prescription disclosure and MRO review
A confirmed positive for hydrocodone or hydromorphone in a regulated program is not automatically reported as a verified positive. It goes to a Medical Review Officer, a licensed physician trained to review laboratory results and interview the donor about any current prescriptions before a final determination is made. If the donor has a legitimate, currently valid prescription for hydrocodone or a hydrocodone combination product, the MRO can verify the result as negative for testing purposes rather than positive.
The DOT rulemaking that added these analytes spent considerable attention on exactly this MRO process, because hydrocodone and the other semi-synthetic opioids are Schedule II drugs that are frequently prescribed and can be legitimately retained and used well after the original fill date. Commenters raised questions about how old a prescription could be and still count as a legitimate medical explanation, and about MRO training requirements specific to these analytes, all discussed in the same Federal Register final rule. Even when a result is downgraded from non-negative to negative because of a valid prescription, the MRO may still be required to flag safety concerns to the employer for safety-sensitive positions, since a hydrocodone prescription can carry impairment implications regardless of whether it explains the lab result. Programs building out MRO workflows around this expanded panel should have a clear internal process for how these calls get documented and escalated, and a general walkthrough of that review sequence is available in this explanation of the Medical Review Officer process.
What this means for your testing program
If your organization only runs a 5-panel or basic OPI-only screen, hydrocodone use is likely going undetected. Employers, clinics, courts, and treatment programs that specifically want to catch hydrocodone, along with the other three semi-synthetic opioids added since the panel expansion, need a cup or panel configuration that lists HYD and OXY as separate lines rather than relying on the legacy OPI strip alone. Reviewing your current panel configuration against the cutoff table above is a reasonable first step before assuming your existing supply already covers these analytes.
Frequently asked questions
Does a standard opiate drug test detect hydrocodone?
Not reliably. The classic OPI immunoassay is calibrated to morphine and does not cross-react strongly enough with hydrocodone's molecular structure to consistently produce a positive result. A panel needs a dedicated HYD line to catch hydrocodone specifically.
What is the difference between an OPI panel and a HYD panel?
OPI targets codeine and morphine at a 2,000 ng/mL cutoff. HYD targets hydrocodone and its active metabolite hydromorphone as a separate group, with a 300 ng/mL initial screening cutoff and a 100 ng/mL confirmatory cutoff per analyte. They are calibrated to different compounds and do not substitute for each other.
Does DOT drug testing include hydrocodone?
Yes. DOT-regulated testing under 49 CFR Part 40 has included hydrocodone, hydromorphone, oxycodone, and oxymorphone since the expanded panel took effect on January 1, 2018.
Will a hydrocodone prescription cause a positive result to be reported to my employer?
Not automatically. A confirmed positive first goes to a Medical Review Officer, who reviews the result and interviews the donor about current prescriptions. A legitimate, valid prescription typically results in the test being verified as negative for reporting purposes, though safety-sensitive positions may still require additional review.
What is norhydrocodone and does it matter for testing?
Norhydrocodone is an inactive metabolite of hydrocodone, formed through a liver enzyme pathway separate from the one that produces hydromorphone. It has no analgesic effect on its own, and standard confirmatory testing typically focuses on the parent drug and hydromorphone rather than norhydrocodone.
Related reading
This article is general information, not legal or medical advice. Panel selection and MRO decisions should be made in consultation with a qualified medical review officer, compliance professional, or legal counsel familiar with your program's governing regulations.
